tiprankstipranks
SkinBioTherapeutics Concludes Convertible Bond Facility
Company Announcements

SkinBioTherapeutics Concludes Convertible Bond Facility

SkinBioTherapeutics (GB:SBTX) has released an update.

Don't Miss our Black Friday Offers:

SkinBioTherapeutics plc has finalized the conversion of its £5.0 million convertible bond facility by issuing 5,848,620 new ordinary shares, with the admission of these shares to AIM expected on 26 July 2024. The company decided against further draws from the facility respecting shareholder sentiment and has successfully cleared the bond with the support of existing and new institutional investors. The total voting rights in the company will now be based on 211,210,526 issued shares post-admission.

For further insights into GB:SBTX stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskSkinBioTherapeutics and Croda Secure Key Commercial Deal
TipRanks UK Auto-Generated NewsdeskSkinBioTherapeutics Voting Rights Shift Slightly
TipRanks UK Auto-Generated NewsdeskSkinBioTherapeutics Expands with Strategic Acquisitions and Growth
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App